Routine vaccination against MenB

Kaaijk, Patricia; Van Der Ende, Arie; Luytjes, Willem
February 2014
Human Vaccines & Immunotherapeutics;Feb2014, Vol. 10 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • Mucosal Immunity in Healthy Adults after Parenteral Vaccination with Outer-Membrane Vesicles from Neisseria meningitidis Serogroup B. Davenport, Victoria; Groves, Eleanor; Horton, Rachel E.; Hobbs, Christopher G.; Guthrie, Terry; Findlow, Jamie; Borrow, Ray; Næss, Lisbeth M.; Oster, Philipp; Heyderman, Robert S.; Williams, Neil A. // Journal of Infectious Diseases;9/1/2008, Vol. 198 Issue 5, p731 

    Background. Nasopharyngeal carriage of meningococcus or related species leads to protective immunity in adolescence or early adulthood. This natural immunity is associated with mucosal and systemic T cell memory. Whether parenteral Neisseria meningitidis serogroup B (MenB) vaccination influences...

  • ACIP weighs in on meningococcal B vaccines. Campos-Outcalt, Doug // Journal of Family Practice;Dec2015, Vol. 64 Issue 12, p787 

    Although not recommended for routine vaccination, either of the 2 approved MenB vaccines may be considered by individuals 16 to 23 years of age, and would be indicated for those ≥10 years at high risk for meningococcal infection.

  • Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme. Tirani, Marcello; Meregaglia, Michela; Melegaro, Alessia // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Introduction: In January 2013 a novel type of multicomponent protein-based vaccine against group B meningococcal disease was licensed by the European Medicines Agency. With the widespread use of the meningococcal serogroup C conjugate vaccines, serogroup B remains now the major cause of...

  • Enter B and W: two new meningococcal vaccine programmes launched. Ladhani, Shamez N.; Ramsay, Mary; Borrow, Ray; Riordan, Andrew; Watson, John M.; Pollard, Andrew J. // Archives of Disease in Childhood;Jan2016, Vol. 101 Issue 1, p91 

    In 2015, the UK became the first country in the world to have a comprehensive routine meningococcal vaccine programme targeting all of the main capsular groups of N. meningitidis. 1 An infant vaccine programme against meningococcal capsular group B Neisseria meningitidis (MenB) was launched from...

  • Saving lives from meningitis in 2015. Wright, Claire; Glennie, Linda // Practice Nursing;Sep2015, Vol. 26 Issue 9, p422 

    The author reports on the 2015 milestones achieved in the fight against meningococcal meningitis and septicaemia. Topics covered are the MenACWY vaccination and the success in eliminating meningococcal C, the introduction of genome based, universally protective Men B vaccine Bexsero and the...

  • Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules. Gossger, Nicoletta; Snape, Matthew D.; Yu, Ly-Mee; Finn, Adam; Bona, Gianni; Esposito, Susanna; Principi, Nicola; Diez-Domingo, Javier; Sokal, Etienne; Becker, Birgitta; Kieninger, Dorothee; Prymula, Roman; Dull, Peter; Ypma, Ellen; Toneatto, Daniela; Kimura, Alan; Pollard, Andrew J. // JAMA: Journal of the American Medical Association;2/8/2012, Vol. 307 Issue 6, p573 

    The article presents the study which determined the immunogenicity and reactogenecity of a multicomponent serogroup B Neisseria meningitidis (MenB) vaccine (4CMenB), as well as routine infant vaccines as given concomitantly or independently. The MenB vaccine is based on detergent-extracted outer...

  • Multicenter, Open-Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy. Findlow, Jamie; Borrow, Ray; Snape, Matthew D.; Dawson, Tom; Holland, Ann; John, Tessa M.; Evans, Anita; Telford, Karen L.; Ypma, Ellen; Toneatto, Daniela; Oster, Philipp; Miller, Elizabeth; Pollard, Andrew J. // Clinical Infectious Diseases;11/15/2010, Vol. 51 Issue 10, p1127 

    Background. In the absence of an efficacious broadly protective vaccine, serogroup B Neisseria meningitidis (MenB) is the leading cause of bacterial meningitis and septicemia in many industrialized countries. An investigational recombinant vaccine that contains 3 central proteins; Neisserial...

  • Tetanus booster doses can resume. C.A.T. // American Journal of Health-System Pharmacy;8/1/2002, Vol. 59 Issue 15, p1412 

    Reports on the resumption of routine vaccination against tetanus and diphtheria for adolescents and adults in the United States. Amount of vaccine produced by Aventis Pasteur.

  • Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. Harris, Shannon L.; Tan, Cuiwen; Perez, John; Radley, David; Jansen, Kathrin U.; Anderson, Annaliesa S.; Jones, Thomas R. // NPJ Vaccines;1/29/2020, Vol. 5 Issue 1, p1 

    MenB-FHbp is a recombinant meningococcal serogroup B (MenB) vaccine composed of 2 factor H binding proteins (FHbps). Meningococcal vaccines targeting polysaccharide serogroup A, C, Y, and W capsules were licensed upon confirmation of bactericidal antibody induction after initial efficacy studies...

  • New generation of outer-membrane vesicles-based meningococcal vaccines. Poolman, Jan; Denoël, Philippe; Devos, Nathalie; Feron, Christiane; Goraj, Karine; Momin, Patricia; Tans, Christine; Weynants, Vincent // Revista VacciMonitor (Vacunología y Temas Afines);May-Aug2009, Vol. 18 Issue 2, p66 

    With the development of conjugate vaccines, Neisseria meningitidis serogroup B (MenB) will remain the major cause of meningitis, as it is not covered by vaccination. In order to develop a vaccine able to confer a broad cross-protection against invasive MenB strains, we have developed a new...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics